● |
U.S. expected to return to revenue and profit growth1 in H1 and FY25, driven by strengthening
Combustibles delivery and an excellent Velo Plus performance
|
● |
Strong global growth from Velo in Modern Oral, the fastest growing New Category segment
|
● |
Continued strong performance in AME; APMEA impacted by excise and regulatory challenges in Bangladesh and Australia, as previously guided
|
● |
Low-single digit H1 New Categories revenue growth, with the impact of illicit Vapour products in the U.S. and Canada partly offsetting excellent Velo performance
|
● |
Accelerating H2 New Category revenue driven by deployment of innovations in key markets
|
● |
Further improvement in New Category contribution margin2, driven by our Quality Growth focus
|
● |
Confident in delivering mid-term algorithm of 3-5% revenue growth and 4-6% APFO3 growth in 2026
|
● |
Partial monetisation of our ITC stake enabling increased financial flexibility
|
● |
Strong cash generation with balanced capital allocation; committed to reducing leverage4 to 2-2.5x by end
2026, with progressive dividend and sustainable share buy-backs – increased to £1.1bn in 2025
|
● |
Group volume share in top markets6 -10bps, value share -10bps
|
● |
U.S. value share +10bps; volume share +10bps (+60bps excl. deep discount where we are not present)
|
● |
U.S. expected to return to revenue and profit1 growth in H1 and FY, driven by successful execution of
commercial actions
|
● |
Resilient AME financial performance led by Brazil, Türkiye and Romania
|
● |
APMEA performance impacted by material excise increases and regulatory headwinds in Bangladesh and Australia, as previously guided
|
● |
Volume share +270bps to 14.3% of Total Oral and +350bps to 29.7% of Modern Oral in top markets7
|
● |
Strong double-digit revenue growth, driven by industry growth and volume share gains
|
● |
Delivering encouraging results in the U.S., driven by Velo Plus, with strong trial and retention rates driving total volume share of Modern Oral +550bps to 11.9% and triple-digit revenue
growth
|
● |
Continued leadership in AME, with strong financial performance in Scandinavia, the UK and Poland
|
● |
Volume share in top markets8 -90bps, driven by a highly competitive environment in Japan and the
continued phase-out of our legacy, super-slims platform
|
● |
AME volume share -10bps, with continued share growth in Poland, Czech Republic and Spain, and a stable share performance in Italy, offset by competitive dynamics in Germany and Romania
|
● |
Encouraging performance from glo Hilo launch in Serbia, doubling previous trial to conversion rates
|
● |
Expect low-single digit revenue growth in H1 with H2 acceleration driven by the phased roll-out of glo Hilo in key markets
|
● |
Global value share in top markets9 flat , with continued global leadership in tracked channels
|
● |
U.S. value share flat, AME +10bps, driven by Europe +40bps
|
● |
Expect mid-teens revenue decline in H1, mostly driven by illicit Vapour headwinds in U.S. and Canada
|
● |
Improving H2 revenue performance, driven by the phased roll-out of our new premium Vapour product, Vuse Ultra, and continued targeted resource allocation
|
● |
On track to deliver operating cash flow conversion10 in excess of 90% again in FY25, reflecting strong
cash discipline and maintaining a laser focus on returns
|
● |
We expect to be back within our 2.0-2.5x adjusted net debt/adjusted EBITDA4 target range by end 2026,
together with a progressive dividend and sustainable share buy-back, increased to £1.1bn in 2025
|
● |
Global tobacco industry volume expected to be down c.2%
|
● |
1-2% Group revenue growth for H1 and FY, at constant rates (previously c.1%)
|
● |
Low-single digit New Category revenue growth in H1; accelerating to mid-single digit for FY
|
● |
1.5-2.5% adjusted profit from operations growth3 at constant rates for FY, weighted to H2, incl. a
c.1.5% transactional FX11 headwind
|
● |
Translational FX11 headwind of c.4% on half-year and full-year adjusted profit from operations3
|
● |
Net finance costs3 of c.£1.8bn, subject to FX and interest rate volatility
|
● |
Operating cash flow conversion10 in excess of 90%, gross capital expenditure in 2025 of c.£650 million
|
● |
Continue to deleverage4 to our 2.0-2.5x adjusted net debt/adjusted EBITDA target corridor by end 2026
|
Six months ended 30 June 2024
|
|||||
Group
Reported
|
Adj Items*
|
Adjusted
|
Adj for
Canada
|
As adjusted
for Canada
|
|
£m
|
£m
|
£m
|
£m
|
£m
|
|
Profit from Operations
|
|||||
U.S.
|
1,775
|
1,278
|
3,053
|
—
|
3,053
|
AME
|
1,473
|
14
|
1,487
|
(232)
|
1,255
|
APMEA
|
1,010
|
14
|
1,024
|
—
|
1,024
|
Total Region
|
4,258
|
1,306
|
5,564
|
(232)
|
5,332
|
Net finance costs
|
(305)
|
(516)
|
(821)
|
(66)
|
(887)
|
Associates and joint ventures
|
1,647
|
(1,367)
|
280
|
—
|
280
|
Profit before tax
|
5,600
|
(577)
|
5,023
|
(298)
|
4,725
|
Taxation
|
(1,041)
|
(115)
|
(1,156)
|
77
|
(1,079)
|
Non-controlling interests
|
(67)
|
—
|
(67)
|
—
|
(67)
|
Coupons relating to hybrid bonds net of tax
|
(21)
|
—
|
(21)
|
—
|
(21)
|
Profit attributable to shareholders
|
4,471
|
(692)
|
3,779
|
(221)
|
3,558
|
Diluted number of shares (m)
|
2,232
|
2,232
|
2,232
|
||
Diluted earnings per share (pence)
|
200.3
|
169.3
|
159.4
|
Six months ended 30 June 2024
|
Group
reported
£m
|
Combustibles
£m
|
New
Categories
£m
|
Traditional
Oral
£m
|
Other
£m
|
Revenue
|
12,340
|
9,856
|
1,651
|
555
|
278
|
Profit from Operations
|
4,258
|
||||
Operating margin
|
34.5%
|
||||
Adjusting items
|
1,306
|
||||
Adjustments in respect of Canada
|
(232)
|
||||
Adjusted profit from operations (as adj for Canada)
|
5,332
|
||||
Adj. operating margin (as adj for Canada)
|
48.6%
|
||||
Other costs that are not attributable to categories
|
901
|
||||
Category Contribution (as adj for Canada)
|
6,233
|
5,573
|
129
|
427
|
104
|
Cat Contribution margin (as adj for Canada)
|
50.5%
|
56.6%
|
7.8%
|
76.9%
|
37.4%
|
Category spend (Marketing Investment and R&D)
|
1,812
|
952
|
813
|
26
|
21
|
Adjusted gross profit (as adj for Canada)
|
8,045
|
6,525
|
942
|
453
|
125
|
Adjusted gross margin (as adj for Canada)
|
65.2%
|
66.2%
|
57.1%
|
81.6%
|
45.0%
|
Year ended 31 December 2024
|
Group
reported
£m
|
Combustibles
£m
|
New
Categories
£m
|
Traditional
Oral
£m
|
Other
£m
|
Revenue
|
25,867
|
20,685
|
3,432
|
1,092
|
658
|
Profit from Operations
|
2,736
|
||||
Operating margin
|
10.6%
|
||||
Adjusting items
|
9,154
|
||||
Adjustments in respect of Canada
|
(520)
|
||||
Adjusted profit from operations (as adj for Canada)
|
11,370
|
||||
Adj. operating margin (as adj for Canada)
|
44.0%
|
||||
Other costs that are not attributable to categories
|
1,848
|
||||
Category Contribution (as adj for Canada)
|
13,218
|
11,931
|
249
|
840
|
198
|
Cat Contribution margin (as adj for Canada)
|
51.1%
|
57.7%
|
7.3%
|
76.9%
|
30.1%
|
Category spend (Marketing Investment and R&D)
|
3,747
|
1,947
|
1,683
|
58
|
59
|
Adjusted gross profit (as adj for Canada)
|
16,965
|
13,878
|
1,932
|
898
|
257
|
Adjusted gross margin (as adj for Canada)
|
65.6%
|
67.1%
|
56.3%
|
82.2%
|
39.1%
|